{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:23:50Z","timestamp":1794565430793,"version":"4.9.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004836","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","award":["1052-00035B"],"award-info":[{"award-number":["1052-00035B"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.diabres.2026.113341","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T07:31:51Z","timestamp":1779780711000},"page":"113341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Comprehensive drug safety assessment of sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and dipeptidyl peptidase 4 inhibitors: A Danish population-based active comparator new user cohort study"],"prefix":"10.1016","volume":"237","author":[{"given":"Lars Christian","family":"Lund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0254-0479","authenticated-orcid":false,"given":"Emma","family":"Simonsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9314-5679","authenticated-orcid":false,"given":"Anton","family":"Potteg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10354","key":"10.1016\/j.diabres.2026.113341_b0005","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.diabres.2026.113341_b0010","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.diabres.2026.113341_b0015","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1111\/dom.14947","article-title":"Changes in the use of glucose\u2010lowering drugs: a Danish nationwide study","volume":"25","author":"Potteg\u00e5rd","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2026.113341_b0020","article-title":"Glucose-lowering drug use, glycemic outcomes, and severe hypoglycemia: 18-Year trends in 0\u00b79 million adults with Diabetes in Hong Kong (2002\u20132019)","volume":"26","author":"Yang","year":"2022","journal-title":"Lancet Reg Health - West Pac"},{"issue":"8","key":"10.1016\/j.diabres.2026.113341_b0025","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.2337\/dc20-2926","article-title":"Trends in first-line glucose-lowering drug use in adults with type 2 diabetes in light of emerging evidence for SGLT-2i and GLP-1RA","volume":"44","author":"Shin","year":"2021","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.diabres.2026.113341_b0030","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1046\/j.1365-2125.1997.05417.x","article-title":"Under\u2010reporting of adverse drug reactions in general practice","volume":"43","author":"Moride","year":"1997","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.diabres.2026.113341_b0035","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/(SICI)1099-1557(199603)5:2<79::AID-PDS219>3.0.CO;2-T","article-title":"Spontaneous reports of drug-induced erythema multiforme, Stevens - Johnson syndrome and toxic epidermal necrolysis in Denmark 1968-1991","volume":"5","author":"Gaist","year":"1996","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.diabres.2026.113341_b0040","doi-asserted-by":"crossref","DOI":"10.1177\/2042098619864744","article-title":"Hypothesis-free signal detection in healthcare databases: finding its value for pharmacovigilance","volume":"10","author":"Bate","year":"2019","journal-title":"Ther Adv Drug Saf"},{"issue":"3","key":"10.1016\/j.diabres.2026.113341_b0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229621","article-title":"Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: a Danish nationwide population-based study. Shimosawa T, ed","volume":"15","author":"Knudsen","year":"2020","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.diabres.2026.113341_b0050","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1093\/aje\/kwae087","article-title":"Building transparency and reproducibility into the practice of pharmacoepidemiology and outcomes research","volume":"193","author":"Wang","year":"2024","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.diabres.2026.113341_b0055","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyw213","article-title":"Data resource profile: the Danish national prescription registry","author":"Potteg\u00e5rd","year":"2016","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.diabres.2026.113341_b0060","article-title":"The Danish National Patient Registry: a review of content, data quality, and research potential","volume":"449","author":"Schmidt","year":"2015","journal-title":"Clin Epidemiol"},{"issue":"8","key":"10.1016\/j.diabres.2026.113341_b0065","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","article-title":"The Danish civil registration system as a tool in epidemiology","volume":"29","author":"Schmidt","year":"2014","journal-title":"Eur J Epidemiol"},{"issue":"4","key":"10.1016\/j.diabres.2026.113341_b0070","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/EDE.0b013e3181a663cc","article-title":"High-dimensional propensity score adjustment in studies of treatment effects using health care claims data","volume":"20","author":"Schneeweiss","year":"2009","journal-title":"Epidemiology"},{"key":"10.1016\/j.diabres.2026.113341_b0075","doi-asserted-by":"crossref","first-page":"l5657","DOI":"10.1136\/bmj.l5657","article-title":"Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners","author":"Desai","year":"2019","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.diabres.2026.113341_b0080","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.1736","article-title":"Adverse events with use of antiepileptic drugs: a prescription and event symmetry analysis","volume":"18","author":"Tsiropoulos","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"10.1016\/j.diabres.2026.113341_b0085","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/pds.5578","article-title":"Recommendations on the calculation of confidence intervals for sequence symmetry analyses","volume":"32","author":"Lund","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"10.1016\/j.diabres.2026.113341_b0090","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s10654-019-00517-2","article-title":"Frequentist versus Bayesian approaches to multiple testing","volume":"34","author":"Sj\u00f6lander","year":"2019","journal-title":"Eur J Epidemiol"},{"issue":"3","key":"10.1016\/j.diabres.2026.113341_b0095","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1001\/jamainternmed.2024.7381","article-title":"Effectiveness of Empagliflozin vs Dapagliflozin for kidney outcomes in type 2 diabetes","volume":"185","author":"Bonnesen","year":"2025","journal-title":"JAMA Intern Med"},{"issue":"6","key":"10.1016\/j.diabres.2026.113341_b0100","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.diabet.2017.05.013","article-title":"Dipeptidyl peptidase-4 inhibitors and risk of arthralgia: a systematic review and meta-analysis","volume":"43","author":"Men","year":"2017","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabres.2026.113341_b0105","unstructured":"Ljungberg C, N\u00f8rgaard M, Vandenbroucke-Grauls C, et al. Risk of Phimosis Associated With SGLT2i Versus GLP-1RA: A Danish Cohort Study."},{"issue":"6","key":"10.1016\/j.diabres.2026.113341_b0110","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/2767-9764.CRC-22-0026","article-title":"Identification of drug\u2013cancer associations: a nationwide screening study","volume":"2","author":"Kristensen","year":"2022","journal-title":"Cancer Res Commun"},{"issue":"5","key":"10.1016\/j.diabres.2026.113341_b0115","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1111\/dom.14982","article-title":"Identifying diabetogenic drugs using real world health care databases: a Danish and Australian symmetry analysis","volume":"25","author":"Lund","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.diabres.2026.113341_b0120","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10654-018-0386-8","article-title":"Hypothesis-free screening of large administrative databases for unsuspected drug-outcome associations","volume":"33","author":"Hallas","year":"2018","journal-title":"Eur J Epidemiol"},{"issue":"9","key":"10.1016\/j.diabres.2026.113341_b0125","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1111\/bcp.13634","article-title":"Identifying signals of interest when screening for drug\u2010outcome associations in health care data","volume":"84","author":"Potteg\u00e5rd","year":"2018","journal-title":"Br J Clin Pharmacol"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726002615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726002615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:27:12Z","timestamp":1794562032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726002615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":25,"alternative-id":["S0168822726002615"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113341","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive drug safety assessment of sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and dipeptidyl peptidase 4 inhibitors: A Danish population-based active comparator new user cohort study","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113341","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113341"}}